CH4 Natural Solutions (MTNE) details $220M SPAC trust and going concern risk
CH4 Natural Solutions Corporation, a Cayman Islands-based blank check company trading on the NYSE as MTNE, reported a small operating loss as it prepared for its initial public offering. For the three months ended March 31, 2026, the company recorded general and administrative expenses of $100,452, resulting in a net loss of the same amount, similar to the prior-year period.
At March 31, 2026, total assets were $1.1 million, primarily deferred offering costs, with no cash on the balance sheet and current liabilities of about $1.48 million, leading to a shareholders’ deficit of roughly $372,000. After quarter-end, CH4 completed its SPAC IPO and a partial over-allotment, raising $220 million into a Trust Account to fund a future business combination. The company discloses substantial doubt about its ability to continue as a going concern over the next year without additional support from its sponsor or affiliates.
Positive
- None.
Negative
- Going concern uncertainty: Management concludes that limited working capital and dependence on potential sponsor loans raise substantial doubt about CH4 Natural Solutions’ ability to continue as a going concern within one year of the financial statement issuance date.
Insights
Pre-revenue SPAC with full $220M trust but going concern risk.
CH4 Natural Solutions is an early-stage SPAC that completed a $220,000,000 IPO and partial over-allotment after quarter-end, placing those proceeds in a Trust Account for a future business combination. Financial activity so far is limited to formation and offering-related costs.
For the quarter ended March 31, 2026, it posted a net loss of $100,452 from general and administrative expenses, reflecting public-company readiness rather than operating setbacks. However, at quarter-end it had no cash, a shareholders’ deficit of about $372,000, and current liabilities exceeding assets.
Management explicitly states that limited working capital and reliance on potential sponsor loans raise substantial doubt about the company’s ability to continue as a going concern within one year of the financial statement issuance. While typical for pre-merger SPACs, investors must recognize that execution now depends on sponsor funding and the ability to close a suitable deal within the 24‑month SPAC timeline.
Key Figures
Key Terms
blank check company financial
Trust Account financial
going concern financial
emerging growth company regulatory
founder shares financial
over-allotment option financial
Earnings Snapshot
FAQ
What did CH4 Natural Solutions (MTNE) report for its Q1 2026 results?
How much capital has CH4 Natural Solutions (MTNE) raised in its SPAC IPO?
What is CH4 Natural Solutions’ financial position as of March 31, 2026?
Does CH4 Natural Solutions (MTNE) face going concern risks?
How is the $220 million Trust Account used by CH4 Natural Solutions (MTNE)?
What are the key SPAC terms for CH4 Natural Solutions (MTNE) shareholders?
Table of Contents
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
th FloorNY |
||
(Address of principal executive offices) |
(Zip Code) | |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
one-half of one warrant |
||||
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
| Emerging growth company | ||||||
Table of Contents
CH4 NATURAL SOLUTIONS CORPORATION
Quarterly Report on Form 10-Q
Table of Contents
| Page | ||||||
| PART 1 - FINANCIAL INFORMATION |
||||||
| Item 1. |
CONDENSED FINANCIAL STATEMENTS | |||||
| Condensed Balance Sheets as of March 31, 2026 (unaudited) and December 31, 2025 | 1 | |||||
| Unaudited Condensed Statements of Operations for the three month periods ended March 31, 2026 and March 31, 2025 | 2 | |||||
| Unaudited Condensed Statements of Changes in Shareholders’ Deficit for the three month periods ended March 31, 2026 and March 31, 2025 | 3 | |||||
| Unaudited Condensed Statements of Cash Flows for the three month periods ended March 31, 2026 and March 31, 2025 | 4 | |||||
| Notes to Unaudited Condensed Financial Statements | 5 | |||||
| Item 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 16 | ||||
| Item 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 20 | ||||
| Item 4. |
CONTROLS AND PROCEDURES | 20 | ||||
| PART II - OTHER INFORMATION |
||||||
| Item 1. |
LEGAL PROCEEDINGS | 20 | ||||
| Item 1A. |
RISK FACTORS | 20 | ||||
| Item 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | 20 | ||||
| Item 3. |
DEFAULTS UPON SENIOR SECURITIES | 20 | ||||
| Item 4. |
MINE SAFETY DISCLOSURES | 21 | ||||
| Item 5. |
OTHER INFORMATION | 21 | ||||
| Item 6. |
EXHIBITS | 22 | ||||
| SIGNATURES |
24 | |||||
i
Table of Contents
MARCH 31, 2026 (unaudited) |
DECEMBER 31, 2025 |
|||||||
ASSETS |
||||||||
Current asset—prepaid expenses |
$ | $ | ||||||
Deferred offering costs |
||||||||
Total assets |
$ | $ | ||||||
LIABILITIES AND SHAREHOLDERS’ DEFICIT |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Promissory note - related party |
||||||||
Due to related party |
||||||||
Total current liabilities |
||||||||
Commitments and Contingencies (Note 6) |
||||||||
Shareholders’ Deficit |
||||||||
Preference shares, $ |
||||||||
Class A ordinary shares, $ |
||||||||
Class B ordinary shares, $ |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
Total shareholders’ deficit |
( |
) | ( |
) | ||||
Total Liabilities and Shareholders’ Deficit |
$ | $ | ||||||
| (1) | This number includes an aggregate of ordinary shares that were subject to forfeiture if the over-allotment option was not exercised in full by the underwriter. On May 6, 2026, the underwriter partially exercised the over-allotment option and on May 8, 2026, purchased |
| (2) | In November 2025, the Company effected a share dividend with respect to the Company’s founder shares of per-share data have been retrospectively presented. |
Three Months Ended March 31, 2026 |
Three Months Ended March 31, 2025 |
|||||||
General and administrative expenses |
$ | $ | ||||||
Net loss |
( |
) | ( |
) | ||||
Weighted average shares outstanding of Class B ordinary shares (1)(2) |
||||||||
Basic and diluted net income per share, Class B ordinary shares |
$ |
( |
) |
$ |
( |
) | ||
| (1) | This number excludes an aggregate of ordinary shares that were subject to forfeiture if the over-allotment option was not exercised in full by the underwriter. On May 6, 2026, the underwriter partially exercised the over-allotment option and on May 8, 2026, purchased |
(2) |
In November 2025, the Company effected a share dividend with respect to the Company’s founder shares of per-share data have been retrospectively presented. |
Ordinary Shares |
Additional Paid-In Capital |
Accumulated Deficit |
Total Shareholder’s Deficit |
|||||||||||||||||||||||||
Class A |
Class B |
|||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
| Balance as of January 1, 2026 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| Net loss |
— |
— |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance as of March 31, 2026 (unaudited) |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
Ordinary Shares |
Additional Paid-In Capital |
Accumulated Deficit |
Total Shareholder’s Deficit |
|||||||||||||||||||||||||
Class A |
Class B |
|||||||||||||||||||||||||||
Shares |
Amount |
Shares |
Amount |
|||||||||||||||||||||||||
| Balance as of January 1, 2025 |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| Net loss |
— |
— |
— |
— |
— |
( |
) |
( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| Balance as of March 31, 2025 (unaudited) |
$ |
$ |
$ |
$ |
( |
) |
$ |
( |
) | |||||||||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| (1) | This number includes an aggregate of ordinary shares that were subject to forfeiture if the over-allotment option was not exercised in full by the underwriter. On May 6, 2026, the underwriter partially exercised the over-allotment option and on May 8, 2026, purchased |
| (2) | In November 2025, the Company effected a share dividend with respect to the Company’s founder shares of per-share data have been retrospectively presented. |
THREE MONTHS ENDED MARCH 31, 2026 |
THREE MONTHS ENDED MARCH 31, 2025 |
|||||||
| Cash Flows from Operating Activities |
||||||||
| Net loss |
$ | ( |
) | $ | ( |
) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
| General and administrative expenses paid directly through due to related party |
||||||||
| Changes in operating assets and liabilities: |
||||||||
| Accounts payable |
||||||||
| Accrued Expenses |
||||||||
| |
|
|
|
|
|
|
|
|
| Net cash used in operating activities |
||||||||
| |
|
|
|
|||||
| Net increase in cash |
||||||||
| Cash - beginning of period |
||||||||
| |
|
|
|
|||||
| Cash - end of period |
$ | $ | ||||||
| |
|
|
|
|||||
| Supplemental disclosure of noncash investing and financing activities: |
||||||||
| Deferred offering costs included in accrued expenses |
$ | $ | ||||||
| |
|
|
|
|||||
| • | Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; |
| • | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
| • | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
| • | in whole and not in part; |
| • | at a price of $ |
| • | upon not less than 30 days’ prior written notice of redemption (the “ redemption period”); and |
| • | if, and only if, the last reported sale price of the Class A ordinary shares equals or exceeds $ |
March 31, 2026 |
December 31, 2025 |
|||||||
| Deferred offering costs |
$ | $ | ||||||
For the three months ended March 31, 2026 |
For the three months ended March 31, 2025 |
|||||||
| General and administrative expenses |
$ | |
$ | |||||
Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
References in this Quarterly Report to “MTNE,” “our,” “us,” “the Company” or “we” refer to CH4 Natural Solutions Corporation. References to our “management” or our “management team” refer to our officers and directors, references to the “sponsor” refer to CH4 Natural Solutions Acquisition Sponsor LLC, and references to the “security holdings sponsor” refer to CH4 Natural Solutions Acquisition Security Holdings, LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this Form 10-Q. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission (“SEC”) filings.
Overview
We are a blank check company incorporated as a Cayman Islands exempted company on October 11, 2024 for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). We intend to effectuate our initial Business Combination using cash from the proceeds of the IPO and the sale of the private placement units, our shares, debt or a combination of the foregoing.
The issuance of additional shares in connection with a Business Combination to the owners of the target or other investors:
| • | may significantly dilute the equity interest of investors, which dilution would increase if the anti-dilution provisions in the Class B ordinary shares (“Founder Shares”) resulted in the issuance of Class A Ordinary Shares on a greater than one-to-one basis upon conversion of the Class B ordinary shares; |
| • | may subordinate the rights of holders of our ordinary shares if preference shares are issued with rights senior to those afforded our Class A Ordinary Shares; |
| • | could cause a change in control if a substantial number of our ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
| • | may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and |
| • | may adversely affect prevailing market prices for our Class A Ordinary Shares and/or warrants. |
Similarly, if we issue debt securities or otherwise incur significant debt to bank or other lenders or the owners of a target, it could result in:
| • | default and foreclosure on our assets if our operating revenues after an initial Business Combination are insufficient to repay our debt obligations; |
| • | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
| • | our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; |
16
Table of Contents
| • | our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
| • | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for expenses, capital expenditures, acquisitions and other general corporate purposes; |
| • | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
| • | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; |
| • | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and |
| • | other disadvantages compared to our competitors who have less debt. |
The registration statement for our initial public offering (“IPO”) was declared effective on April 30, 2026. On May 4, 2026, the Company consummated its IPO of 20,000,000 units (the “units”). The units were sold at a price of $10.00 per unit, generating gross proceeds to the Company of $200,000,000, which is described in Note 3. Each Unit consists of one Class A ordinary share, par value $0.0001 per share (the “Class A ordinary shares”) and one-half of one warrant (“public warrant”) of the Company. Each whole public warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment.
Simultaneously with the closing of the IPO, the Company completed the private sale of 200,000 private placement units (each unit consists of one Class A ordinary share and one-half of one warrant) at a purchase price of $10.00 per private placement unit (the “private placement”) to CH4 Natural Solutions Acquisition Security Holdings, LLC (the “security holdings sponsor”), generating gross proceeds to the Company of $2,000,000, which is described in Note 4. Transaction costs amounted to $8,351,843, including $6,000,000 in deferred underwriting fees, $250,000 in upfront underwriting fees, and $2,101,843 in other offering costs related to the IPO. In addition, cash of $1,750,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.
On May 6, 2026, the underwriter of the IPO (the “Underwriter”) partially exercised the over-allotment option and on May 8, 2026, purchased an additional 2,000,000 units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $20,000,000. The Underwriter has until 45 days after the date of the Company’s Prospectus to exercise on the remaining over-allotment option.
Of the net proceeds of the IPO, the sale of the private placement units and the sale of the over-allotment option units, a total of $220,000,000, including $6,600,000 of deferred underwriting discounts and commissions, was placed in a trust account with Continental Stock Transfer & Trust Company acting as trustee (the “Trust Account”).
Results of Operations
We have neither engaged in any operations nor generated any revenues to date. Our only activities from October 11, 2024 (inception) through March 31, 2026 were organizational activities and those necessary to prepare for the IPO. Subsequent to the IPO, our activities have included the Company’s search for a target business with which to complete an initial Business Combination. We do not expect to generate any operating revenues until after the completion of our initial Business Combination, at the earliest. Following the IPO, we will generate non-operating income in the form of interest income on marketable securities. We are incurring expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses in connection with completing an initial Business Combination.
For the three months ended March 31, 2026, we had $100,452 in general and administrative expenses.
For the three months ended March 31, 2025, we had $98,509 in general and administrative expenses.
17
Table of Contents
Liquidity and Capital Resources
Until the consummation of our IPO, our only source of liquidity was an initial purchase of our Class B ordinary shares, par value $0.0001 per share, by the sponsor and loans from the sponsor, which was subsequently transferred and assigned to an affiliate of the sponsor and repaid.
Subsequent to the quarterly period covered by this Quarterly Report, on May 4, 2026, we consummated the IPO of 20,000,000 units at $10.00 per unit, generating gross proceeds of $200,000,000. Simultaneously with the closing of the IPO, we consummated the sale of an aggregate of 200,000 private placement units at a price of $10.00 per private placement unit, or $2,000,000 in the aggregate, to the security holdings sponsor, in a private placement. On May 8, 2026, we consummated the sale of an additional 2,000,000 units sold pursuant to the underwriter’s partial over-allotment option, generating gross proceeds of $20,000,000. Each private placement unit consists of one private placement share and one-half of one private placement warrant.
Following the IPO and the sale of the private placement units on May 4, 2026 and the partial over-allotment close on May 8, 2026, a total of $220,000,000 is held in the Trust Account. We incurred total transaction costs of $8,951,843, including $6,600,000 in deferred underwriting fees, $250,000 in upfront underwriting fees, and $2,101,843 in other offering costs related to the IPO.
We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less income taxes payable and deferred underwriting discounts and commissions), to complete our Business Combination. We may withdraw interest to pay our taxes, if any. Our annual tax obligations generally will depend on the nature and amount of interest and other income earned on the amounts held in the Trust Account. Based on current interest rates and the taxes we currently expect to be applicable to us, we expect that the interest earned on the Trust Account will be sufficient to pay our taxes. To the extent that our shares or debt is used, in whole or in part, as consideration to complete our initial Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.
We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a business combination.
In order to fund working capital deficiencies or finance transaction costs in connection with an intended initial Business Combination, our sponsor or an affiliate of our sponsor or our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete our initial Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that our initial Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into units of the post-Business Combination entity at a price of $10.00 per unit at the option of the lender. The units and their underlying securities would be identical to the private placement units and their underlying securities, including as to exercise price, exercisability and exercise period with respect to the private placement warrants. The terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of our initial Business Combination, we do not expect to seek loans from parties other than our sponsor or an affiliate of our sponsor as we do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our Trust Account.
We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our public shares upon consummation of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination.
Contractual Obligations
Registration Rights
The holders of the founder shares, private placement units (and their underlying securities) and units that may be issued upon conversion of working capital loans (and their underlying securities) and any Class A ordinary shares held by our initial shareholder at the completion of the IPO or acquired prior to or in connection with our initial Business Combination, will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the registration statement of which the Prospectus forms a part, requiring us to register such securities
18
Table of Contents
for resale (in the case of the founder shares, only after conversion to our Class A ordinary shares). The holders of these securities, having a value of at least $25 million in the aggregate, are entitled to make up to three demands that we offer such securities in an underwritten offering. These holders also have certain “piggyback” registration rights with respect to certain underwritten offerings we may conduct. We will bear the expenses incurred in connection with registering these securities.
Underwriting Agreement
On May 8, 2026, the underwriter purchased 2,000,000 Units in partial exercise of the over-allotment option. The underwriter has a 45-day option from the date of the Prospectus to exercise the remaining over-allotment option.
The Company paid an underwriting discount of $250,000 to the underwriter at the closing of the IPO, with an additional fee of $0.30 per unit sold in the IPO (including both the base and over-allotment units sold), or $6,600,000 in the aggregate, that will be payable to the underwriter for deferred underwriting commissions, which shall be subject to pro rata reduction based on the number of Class A ordinary shares redeemed by the public shareholders.
In addition to the underwriting discounts and commissions, the Company engaged Santander US Capital Markets LLC to provide advisory services from time to time. As compensation for the services provided under an engagement letter, the Company shall pay Santander US Capital Markets LLC a fee equal to 3.00% of the gross proceeds from the IPO, payable upon the completion of an initial Business Combination. The Company agreed to indemnify Santander US Capital Markets LLC and its affiliates in connection with its role in providing such advisory services. Upon the completion of the IPO and the partial exercise of the over-allotment option by the underwriter, the Company recorded a charge against earnings for $6,600,000 which represents the 3.00% advisory fees payable by the Company as such fees are not tied to future services.
Administrative Support Agreement
The Company has entered into an agreement with an affiliate of the sponsor pursuant to which the Company is obligated to, commencing on the date the securities of the Company were first listed on the New York Stock Exchange, pay an aggregate of $10,000 per month for office space, utilities, and secretarial and administrative support. Upon completion of an initial Business Combination or the Company’s liquidation, we will cease paying these monthly fees. No fees were accrued for the three months ended March 31, 2026 and 2025.
Critical Accounting Policies and Estimates
We describe our significant accounting policies in Note 2 - Summary of Significant Accounting Policies, of the Notes to Unaudited Condensed Financial Statements included in this Form 10-Q. Our condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Certain of our accounting policies require that the Company’s management apply significant judgments in defining the appropriate assumptions integral to financial estimates. On an ongoing basis, the Company’s management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. Judgments are based on historical experience, terms of existing contracts, industry trends and information available from outside sources, as appropriate. However, by their nature, judgments are subject to an inherent degree of uncertainty, and, therefore, actual results could differ from our estimates. The Company does not have any critical accounting policies and estimates.
Off-Balance Sheet Arrangements
We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of March 31, 2026. We do not participate in transactions that create relationships with entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
JOBS Act
On April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” under the JOBS Act and are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We elected to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, our unaudited condensed financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
19
Table of Contents
Table of Contents
Item 6. Exhibits
| Exhibit |
Description of Exhibit | |
| 1.1 | Underwriting Agreement, dated April 30, 2026, between the Company and Santander US Capital Markets LLC (incorporated by reference to Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 3.1 | Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 4.1 | Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1 (Commission File No. 333- 284199), filed April 24, 2026). | |
| 4.2 | Specimen Class A Ordinary Shares Certificate (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1 (Commission File No. 333- 284199), filed April 24, 2026). | |
| 4.3 | Specimen Public Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1 (Commission File No. 333- 284199), filed April 24, 2026). | |
| 4.4 | Specimen Private Warrant Certificate (incorporated by reference to Exhibit 4.4 to the Company’s Registration Statement on Form S-1 (Commission File No. 333- 284199), filed April 24, 2026). | |
| 4.5 | Private Warrant Agreement, dated April 30, 2026, between the Company and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 4.6 | Public Warrant Agreement, dated April 30, 2026, between the Company and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 10.1 | Letter Agreement, dated April 30, 2026, among the Company, its officers and directors, the Sponsor and the Security Holdings Sponsor (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 10.2 | Investment Management Trust Agreement, dated April 30, 2026, between the Company and Continental Stock Transfer & Trust Company, as trustee (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 10.3 | Registration Rights Agreement, dated April 30, 2026, among the Company, the Sponsor and the Security Holdings Sponsor (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 10.4 | Administrative Support Agreement, dated April 30, 2026, between the Company and an affiliate of the Sponsor (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 10.5 | Private Placement Units Purchase Agreement, dated April 30, 2026, between the Company and the Security Holdings Sponsor (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026). | |
| 10.6 | Form of Indemnification Agreement (incorporated by reference to Exhibit 10.8 to the Company’s Registration Statement on Form S-1 (Commission File No. 333- 284199), filed April 24, 2026). | |
| 10.7* | Second Amended and Restated Promissory Note, dated June 12, 2026, between the Company and an affiliate of the Sponsor. | |
22
Table of Contents
| 31.1* | Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2* | Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32.1** | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2** | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101* | Interactive Data Files (filed herewith as Exhibit 101). | |
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). | |
| * | Filed herewith |
| ** | These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Exchange Act, nor shall they be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing. |
23
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CH4 NATURAL SOLUTIONS CORPORATION | ||||||
| Date: June 12, 2026 | By: | /s/ Arthuros Mangriotis | ||||
| Name: | Arthuros Mangriotis | |||||
| Title: | Chief Financial Officer, Chief Accounting Officer and Secretary | |||||
24